Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
White House says true cost $504bn opioid drug epidemic in 2015
Here is the article:
https://www.theguardian.com/us-news/2017/nov/20/true-cost-opioid-drug-epidemic-504bn-white-house
Nutra Pharma gets a fraction of the alternative opioid market potential we enter and leave copper for good!!! NUTRA PHARMA BECOMES A SMALL CAP STOCK OVERNIGHT!!!
Many others have been targeting .07 cents. That represents a 140 million market cap. Remember this number does not include the "Orphan Drug Status' or any of other possibilities in the drug pipeline. What if we hit 2-5% of market penetration for Opioid Alternatives? I will let you play with those potential numbers!
There are projections for 50-100 million market cap for the Orphan Drug Status alone today!
21 patents folks of intellectual property in our Portfolio. New patents applied for as well.
Partnership With EuroAmerican to distribute Nyloxin...EuroAmerican IP, LLC has been delivering Federal Supply Schedule Commodities to the BOP, DHS, DOJ, DOD, FBI, USCG, HHS, NIH, SSA, VA and other governmental agencies since 2009. Currently offering over 100 contracted items to VA's and OGA's. EAIP is proud to comment that we have only received excellent feedback and appreciation from loyal customers
We have just left the standard quiet period Now we await the next PR CYCLE. We get great news, JV, financing, opiate alternative market penetration, FDA trials, we will see NPHC leave the launch pad IMHO.
Also realize the pharma's that are losing their opiate revenue generation. Limits are being put on these daily. Some are being restricted completely in states.
Also all the law suites being filed. These Big pharma's will be searching for alternatives!!!
Maybe Nutra Pharma is on the verge of becoming a small to mid size pharma?
For those that have held on over the last several years I do believe the ship is soon to be coming in. Its called timing and being at the right place at the right time!
Mav
Orphan Drug Status - Pediatric MS(RPI-78M)
Look at the other possible neurological disorders this may serve!!
FDA TRIALS PHASE II Soon imo!!!
http://www.receptopharm.com/drug_development/
RPI-78M is being developed for the treatment of Multiple Sclerosis (MS) and Adrenomyeloneuropathy (AMN). Other neurological disorders that may be served by RPI-78M include Myasthenia Gravis (MG) and Amyotrophic Lateral Sclerosis (ALS).
RPI-MN and RPI-78M possess several desirable properties as drugs:
They lack measurable toxicity but are still capable of attaching to and affecting the target site on the nerve cells. This means that patients cannot overdose.
They display no serious adverse side effects following years of investigations in humans and animals.
They are extremely stable and resistant to heat, which gives the drugs a long shelf life. The drugs' stability has been determined to be over 4 years at room temperature. This is extremely unusual for a biologic drug.
They are easy to administer.
RPI-78M can be administered orally a first for a biologic MS drug. This will present MS patients with additional quality of life benefits by eliminating the requirement for routine injections.
RPI-78M
Nutra Pharma's RPI-78M Granted Orphan Drug Status by the US Food and Drug Administration
https://finance.yahoo.com/news/nutra-pharmas-rpi-78m-granted-123000069.html
RPI-78M Collaboration: University of Maryland,production of RPI-78M for the planned upcoming clinical trials in Pediatric Multiple Sclerosis
https://finance.yahoo.com/news/nutra-pharma-announces-collaboration-university-123000318.html
Interesting Older Post on Market Cap Related to the Orphan Drug Status and FDA Trials......
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=133351752
Those numbers were based primarily on the Orphan Drug Status - Pediatric MS going to Phase II FDA trials! When NPHC secures funding to proceed phase II trials forward the PPS will EXPLODE!
I believe news on this front is coming soon...My bet we are worthy of much more than a 5 million market cap. You decide and do your own math!
NPHC CEO said that a company with a Phase 2 drug should have a $100 million dollar market value according to studies.
He also said based on their pipeline they should have a MINIMUM $30 million market value right now. This according to his spring interview last year. Since then our portfolio is GROWN and our distribution channels have EXPANDED
https://stockguru.com/nutra-pharma-ceo-rik-deitsch-interview/
This stock only has a market value of $5million dollars right now based on my estimation of around 2 Big shares outstanding and a .0025 share price. NPHC is ridiculously undervalued at this level. The CEO said it should have a $30 million market value right now. That would put it around .015. Once phase 2 starts it should have a $100 million market value. That would put the share price at .07 per share.
IT IS THE SHAREHOLDERS WHO DECIDE THE WORTH OF A STOCK. The majority of my sell orders will be WAY ABOVE .01. Lock them up and HOLD them. Make the market pay up for our shares, they are worth FAR more than .0025!
Mav
I believe they have already witnessed the incredible results of Nyloxin.
The CEO of EuroAmerican states they have seen that Nyloxin substantially reduces all types of pain without mental, confusion, addiction or toxicity. Folks this sounds like they have had trials and test cases before adding Nyloxin. This is going to be huge.
Quote:
“We are excited to be working with Nutra Pharma,” commented Debra J Paul, CEO, and Tami Dana, COO, of EuroAmerican. “Nyloxin is an exciting alternative to opiate drugs. We believe that it can be a significant tool for combatting opioids in our veterans and in our military,” they continued. “We have seen that Nyloxin substantially reduces all types of pain without mental confusion, addiction or toxicity. We believe that we can quickly and successfully add the Nyloxin products to our existing product list for distribution through our Federal Supply Schedule #V797D-40251 to be available as a replacement for opioids and other pain management drugs,” they concluded.
https://globenewswire.com/news-release/2018/01/18/1296478/0/en/Nutra-Pharma-Partners-with-EuroAmerican-IP-to-Distribute-Nyloxin-for-Sale-to-Government-Agencies.html
Get these results in front of some major decision makers in the federal and state governments.
I have documented where 100's of millions of opioid prescriptions are issued annually. The Federal government states 500 billion annually in costs in the U.S. alone in 2015 for opioids. This is crazy!!!
NPHC HAS A VIABLE ALTERNATIVE!! RIGHT NOW!!
Market Cap under 20 million! NOT FOR LONG.
Mav
2018 is the year for M&A in the pharmaceutical industry
Tax Overhaul Could Jolt Dollar as U.S. Companies Bring Home Cash
Big Pharma Corporations could repatriate as much as $400 billion in earnings and cash from abroad. Check out the details of the tax overhaul in this article:
https://www.wsj.com/articles/tax-overhaul-could-jolt-dollar-as-u-s-companies-bring-home-cash-1514206800
Mergers and acquisitions are anticipated to be huge with pharma and bio-techs...
Why 2018 is a make-or-break year for BIG Pharma:
Many drugmakers have neglected their pipelines, and will look to acquisitions to bolster them
https://www.marketwatch.com/story/why-2018-is-a-make-or-break-year-for-pharma-2017-12-19
FROM ARTCILE:
This year looks — at least on paper — like an unprecedentedly good setup for the pharmaceutical industry.
But behind the scientific breakthroughs, a Food and Drug Administration churning out approvals and drug-price regulation never materializing, the industry appears shockingly fragile.
Some of drugmakers’ most profitable products are aging, or simply old — nearly two decades old, in some cases — and staring down new competition.
Meanwhile, many big companies’ pipelines, typically a source of new development and the next billion-dollar drugs, are dry.
NPHC is poised to be a prime target for M&A in 2018. The IP portfolio and products would be a major addition to a big company looking for opiod alternatives and other disruptive products.
A Merger or acquisition is not out of the question here.
Mav
EuroAmerica is active marketing directly to the veterans at the VA medical centres across the US.
Check this out:
This is potential of Nyloxin revenues from just the VA/Military ALONE!!!
With EuroAmerican and the GOVERNMENT INVOLVED the potential is mind blowing.
6.5 million prescriptions in 2012. We know its more now! Doesn't even include the NSAID's....
Folks we get 1/2 million chronic prescription replacements - yearly supply:
500,000 * $38.25 monthly (45 extra strength*15% discount annual) * 12 (months) = 229,500,000 Revenues 1 year......
Sheesh...lets be really conservative.... If we take 100,000 orders = 45,900,000 revenue (1.5% of 6.5 million).... CRAZY POTENTIAL!!!
This is just from ONE of our products and ONE branch of its potential revenue streams!
NPHC currently at 5 million dollar market cap... Undervalued is a understatement.
The partnership with EuroAmerican just began on Jan 18 2018. Here is the press release:
https://globenewswire.com/news-release/2018/01/18/1296478/0/en/Nutra-Pharma-Partners-with-EuroAmerican-IP-to-Distribute-Nyloxin-for-Sale-to-Government-Agencies.html
2018 is the turn around year for NPHC.
MARK IT.
Mav
9M on the bid at .0022.
It is obvious that traders see these levels as a BUYING opportunity.
When they get impatient and put buying pressure on the ask watch how fast it moves UP
Mav
DSGT...
a two day delay for audited fins.
I can wait! Ready to add! Along with everyone else here!
Nothing is fundementally changed except the sell on the news crews are exiting today... which is a good thing IMHO!!
Mav
Agree 100% brother.
We have been trying to tell everyone all along how CELZ is tbe opportunity of a lifetime.
I am excited to be apart of this company and the amazing future it has in store!
Mav
NPHC released...
A very similar 10k in 2015... back they had 140 million dollar market cap.
Investors here are not looking for a impressive year end balance sheet.
We are investing into the future developments of NPHC's drug pipeline and current expansion of the real products into new distribution channels.
The value of the IP portfolio and the fully audited SEC reporting shell is worth WAY more than a 5 million dollar market cap!!
The opioid alternative pain relief products are poised to be the SOLUTION in midst of a NATIONWIDE OPIOID CRISIS.
the writing is on the wall. Thats why sharks are circling and all the trading manipulation is being used to get as many cheapies as possible.
The trading float is getting tighter and stronger everyday and we are on the verge of a MASSIVE run upon the next PR cycle.
I got my tickets
Mav
Todays trading pattern...
Demonstrated strong buying and very little selling throughout the day ... then 10k came out. Instantly the EOD dumping occured and misinformation spread about the 10k.
EOD trading was another a desparate attempt to shake the tree and get cheap shares before the next news cycle begins. The quiet period is over!!
The risk factors in the 10k are standard disclaimers. I just bought PP shares of a company operating at profit of 700k revenues and they had a similar risk factor statement in their subscription agreement!
Mav
FACTS ABOUT NPHC 10K.
This following information is from the 10k for the fiscal year of 2014 that came out in 2015. At the time the 10k came out NPHC was trading around a 140 million dollar market cap and continued to trade in this range.
NPHC traded at that market cap because of its INTELLECTUAL property. Majority of biotech companies operate at a loss or have zero revenues yet trade at huge market caps because of the POTENTIAL of the drugs and intellectual property they own.
This copy and pasted from the 2014 10k:
Item 1A. Risk Factors
You should carefully consider the risks described below regarding our operations, financial condition, financing, our common stock and other matters. If any of the following or other material risks actually occur, our business, financial condition, or results or operations could be materially adversely affected.
Our ability to continue as a going concern is in doubt absent obtaining adequate new debt or equity financing and achieving sufficient sales levels.
We incurred net losses of $2,532,985 and $4,342,964 for the years ended December 31, 2014 and 2013. We anticipate that these losses will continue for the foreseeable future. We have a significant working capital deficiency, and have not reached a profitable level of operations, which raises substantial doubt about our ability to continue as a going concern. Our continued existence is dependent upon our achieving sufficient sales levels of our Cobroxin ® , Nyloxin ® and Pet Pain Away products and obtaining adequate financing. Unless we can begin to generate material revenue, we may not be able to remain in business. We cannot assure you that we will raise enough money or generate sufficient sales to meet our future working capital needs.
We have a limited revenue producing history with significant losses and expect losses to continue for the foreseeable future.
We have yet to establish any history of profitable operations. We have incurred annual losses of $2,532,985 and $4,342,964 during the fiscal years of operations ending December 31, 2014 and 2013 respectively. As a result, at December 31, 2014 we had an accumulated deficit of $44,519,805. Our revenues have been insufficient to sustain our operations and we expect our revenues will be insufficient to sustain our operations for the foreseeable future. Our potential profitability will require the successful commercialization of our Cobroxin ® , Nyloxin ® and Pet Pain-Away products.
We will require additional financing to sustain our operations and without it will be unable to continue operations.
At December 31, 2014 we had a working capital deficit of $3,610,206. Our recurring losses from operations and working capital deficiency raise substantial doubt about our ability to continue as a going concern. We have a negative cash flow from operations of approximately $0.15 million and $0.53 million for the years ended December 31, 2014 and 2013, respectively. We have insufficient financial resources to fund our operations.
As of December 31, 2014 we owe $411,411 to our Chief Executive Officer from funds borrowed from him.
20
Our Chief Executive Officer may be unwilling or unable to continue funding our operations.
Our Chief Executive Officer has historically funded our operations by providing loans to us. As of December 31, 2014, we owe Mr. Deitsch $411,411. Mr. Deitsch may be unwilling or unable to fund our operations in the future. If we have no other source of funding and we are unable to secure additional loans from Mr. Deitsch, our operations will be negatively affected.
To date, none of our prescription drug candidates have received FDA drug orphan status approval.
To date, none of our prescription drug candidates have received FDA drug orphan status, which would otherwise place our drug candidates on a “fast track” with the FDA application process. If none of our drug candidates can achieve that status, our operations and financial condition will be negatively affected.
We have a history of failed distributors, which has negatively affected our revenues and may continue to do so if we fail to locate a successful distributor.
Due to poor performance, we cancelled our distribution agreement with our Cobroxin ® distributor, XenaCare in April, 2011. We plan to re-launch Cobroxin ® , but we have not yet ordered product or provided planned sales. To date, we have only limited sales of Nyloxin ® and Pet Pain-Away through outside distributors. Most of the current sales are direct from the company or through the www.Nyloxin.com website. If we fail to improve our own marketing and distribution or fail to find a competent outside distributor our operations and financial condition will be negatively affected
If we cannot sell a sufficient volume of our products, we will be unable to continue in business.
To date, sales of Cobroxin ® have been limited and inconsistent. Total sales of Cobroxin ® have been $1,995,673 since the fourth quarter of 2009, with no significant sales since the second quarter of 2010.
To date, sales of Nyloxin ® have been limited and inconsistent. During 2011, we sold $66,568 of Nyloxin ® . During 2012, we sold $199,231 of Nyloxin ® . During 2013, we sold $119,898 of Nyloxin ® . During 2014, we sold $587,804 of Nyloxin ® . We launched Pet Pain-Away in late December of 2014 and generated $6,701 in 2014. If we cannot achieve sufficient sales levels of our Cobroxin ® , Nyloxin ® and Pet Pain-Away products or we are unable to secure financing our operations will be negatively affected.
We have a limited history of generating revenues on which to evaluate our potential for future success and to determine if we will be able to execute our business plan; accordingly, it is difficult to evaluate our future prospects and the risk of success or failure of our business.
Our total sales of Cobroxin ® from November 2009 until December 31, 2014 are $1,995,673. Our total sales of Nyloxin ® from January 1, 2011 to December 31, 2014 are $973,501. You must consider our business and prospects in light of the risks and difficulties we will encounter as an early-stage revenue producing company. These risks include:
·
our ability to effectively and efficiently market and distribute our products;
·
our ability to obtain market acceptance of our current products and future products that may be developed by us; and
·
our ability to sell our products at competitive prices which exceed our per unit costs.
We may be unable to address these risks and difficulties, which could materially and adversely affect our revenue, operating results and our ability to continue to operate our business.
This proves my point. 10k is a formality for a biotech stock. I want someone to show us another biotech company with a comparable IP portfolio that is trading at 5 million dollar market cap....
I am waiting.
Mav
Lots of 10ks...
Have those doom n gloom risk disclaimers in them. Go read a few from around the OTC.
Trading 101
Mav
Go look at last years 10k...
Not much difference.
Those crying bloody murder now were hyping .18 just two months ago with the same information in last years 10k.
Nothing's changed except those traders who sold will be circling for cheapies.
Right on cue.
Mav
NPHC - 10k
It is nearly identical to last year. Anyone who is invested here for a blockbuster 10k doesnt know what the company does.
I am here for what is coming after the 10k. The quiet period is over. Rik its time for the next PR cycle and to deliver the meat and potatoes !
Mav
NYXOLIN is now on the top of http://www.euroamericanproducts.com/
here is the link
http://www.euroamericanproducts.com/nyloxin%C2%AE_-_chronic_pain_relief
Here is why this is HUGE a development:
EuroAmerican IP, LLC has been delivering Federal Supply Schedule Commodities to the BOP, DHS, DOJ, DOD, FBI, USCG, HHS, NIH, SSA, VA and other governmental agencies since 2009. Currently offering over 100 contracted items to VA's and OGA's. EAIP is proud to comment that we have only received excellent feedback and appreciation from loyal customers.
It is a Major market we are presently entering into as we speak.
the Department of Veterans Affairs, and EuroAmerican’s Federal Supply Schedule that are already in bed with http://www.euroamericanproducts.com/
Veterans Affairs had 6.5 million prescriptions in 2012. We know its more now! Doesn't even include the NSAID's... Now we get .5 million chronic prescription replacements - yearly supply:
500,000 * $38.25 monthly (45 extra strength*15% discount annual) * 12 (months) = 229,500,000 Revenues 1 year......
Sheesh... I would take 100,000 orders = 45,900,000 revenue (1.5% of 6.5 million).... CRAZY POTENTIAL!!!
This is just from ONE of our products and ONE branch of its potential revenue streams!
NPHC currently at 5 million dollar market cap... Undervalued is a understatement.
NPHC is a gift at these prices.
Mark it.
Mav
Ask walls...
Have been constantly used to block upward momentum... its happened for a long time
Whoever is been trying to manipulate the price down is loosing grip. I wont be surprised if the fear mongering shows up right on cue.
I am keeping track of it.
I already voiced how i feel about it and how serious I am with dealing with it. Been alot quieter since... if u noticed.
The 10k is due.
Major developments have been ongoing behind the scenes.
The quiet period is over and i believe we are entering into a new PR cycle with serious news due to hit the wires.
Buckle up my friends
NPHC
Mav
Nearinf 500k dollar volume already today
A new base is being formed here for the next leg UP to silver
NPHC.
A few years ago the IP portfolio, over the counter products and assets were VALUED at 140 million market cap.
The IP portfolio is GROWN since then. We have more intellectual property and more patents and patents pending.
The distribution channels for the OTC products have EXPANDED. NPHC is gained access into more markets in the US and abroad.
The opioid crisis is hit a boiling point. There is extreme pressure from the public and the government for opioid alternatives.
The demand for opioid alternatives has increased 10 fold!!
NPHC sits at a 5 million dollar market cap... extremely ridiculously criminally UNDERVALUED here... i believe this is all going to change in very short order.
Rik the time is now. Deliver the 10k and the updates the world is been waiting for!!
Mav
Over a million dollars traded above .01.
YESTERDAY.
Around 25% of the OS.
And some amateurs are selling here not knowing whats coming next.
Holding tight.
Mav
FDA warns companies for selling unapproved opioid alternatives
Here is the article here:
https://www.drugs.com/news/fda-ftc-warn-companies-selling-illegal-unapproved-opioid-cessation-products-using-deceptive-claims-68474.html
NOTICE HOW NPHC IS NOT ON THE LIST!!
Thats because we are a real company with legitimate products!
This is a very big development that will affect our overall sales imo. NPHC has 10 less companies to compete with, 10 Companies that will no longer be selling their non approved opioid alternative products on the market.
This opens the door for our products to gain more attention and a higher percentage of the market! INCREASED REVENUES. Nyloxin works, my family and friends use it and really enjoy it. IT IS REPLACING OPIOID PAINKILLERS IN THEIR HOUSE HOLDS. Imagine what happens with time.... Nyloxin will slowly gain traction and more n more people it is a EFFECTIVE and HEALTHIER alternative pain killer.
THIS IS JUST ONE MORE REASON I AM INVESTED IN NPHC
Mav
NPHC Files Provisional Patent for Nerve Agent Counter Measures
The official Press Release here:
https://globenewswire.com/news-release/2018/02/21/1372579/0/en/Nutra-Pharma-Files-Provisional-Patent-for-Nerve-Agent-Counter-Measures.html
Spy poisoning: Russia stockpiling nerve agent, says Johnson
http://www.bbc.com/news/uk-43448682
The fact that NPHC is filing for a patent for Nerve Agent Counter Measures is a very big development here is why.
1. It proves that behind the scenes NPHC is developing valuable intellectual property
2. It proves that NPHC has high level government connections and is working closely with the US military
3. It proves that NPHC is a legitimate company with very serious products. The security clearance required to work for the US military with highly sensitive information regarding a counter agent to nerve gas... Not many companies get this kind of access and clearance to CLASSIFIED intel.
4. A counter measure to nerve gas would bring in MASSIVE revenues, I can't even predict how much. The potential is unprecedentedly HUGE.
"We have long worked with neuroactive compounds utilized in our drugs for the treatment of neurological diseases like Multiple Sclerosis,” stated Rik J Deitsch, Chief Executive Officer of Nutra Pharma. “In much the same way that our therapies protect the nerves of patients with disease, our findings indicate that we may protect against – or at least mitigate the damage caused by - nerve agents that are utilized as chemical weapons; such as sarin gas and VX,” he continued. “We are now filing new intellectual property surrounding these findings and will be working with experts in the field to have our products in testing shortly. This work will go hand in hand with our efforts to promote our OTC pain therapy, Nyloxin, as an opiate replacement to the US military and veterans,” stated Rik J Deitsch, Chief Executive Officer of Nutra Pharma.
Mav
A great post based on facts...
The majority of information stated here can be backed up by a PR... a email... a 10Q... or government statistics.
Thanks BMOC.
Mav
Eventually real companies and real stocks...
Move beyond the grip of fear mongering social media trolls. People need to understand the game.
Nobody is involved with this stock for pleasure... all of us are here to make money on the stock trade...
Some make $$$ when it goes up... others make money when it goes down.... MMs make money both ways.... this communication interface is a tool used for good and evil. Remember that.
Now time will tell who is right.... the seasoned investors have learned to hold on tight and ride the waves UP to where a stock belongs.
Others.... well grandma said if u dont got nothing nice to say....dont say nothing at all....
Each to their own.
Mav
1.5 million ++ dollar volume today
That is HUGE dollar volume.
Those that sold and hope to reload below are playing a risky game IMO
The desparation shows...
Cheapies make people do crazy things...lol
Im holding tight for silver... MINIMUM.
Mav
Nauseated...
Will be all those who sold down here at 5 million market cap when NPHC begins is long over due market cap correction back to 140 million MC.
Absolutely NOTHING IS FUNDEMENTALLY Changed since NPHC was at 140M market cap.
In fact the IP portfolio has GROWN and Distribution channels for our products have EXPANDED since then.
Its simply a matter of time before we begin the next leg up on our journey back to the correct market cap.
$$$$$$$.07$$$$$$$
NPHC
Mav
Bids building and 27s falling!!!
3.5 milly on the bid and .0027s just got slapped for 2 mil
Nice!!
BMOC...
6.5 million perscription market for the VA/Military was from 2012.
I gaurentee that number is went UP!!! Plus the opiod crisis sweeping the nation!! We definately will see higher numbers than .y conservative 100,000 orders per year.
I just wanted to be conservative and keep it simple... dont want anyone to get lost in the grade 9 math i presented... LOL
Mav
The squeeze is on....
Watch the squirming kicking and screaming with nothin but negative opinions and perspectives.... zero validation.
NPHC is extremely UNDERVALUED and i am waiting for someone to legitimately prove their IP portfolio is worth less than it was just a few yrs ago...
The IP portfolio was at 140 million dollar market cap!!
Currently we sit at 5 million market cap!!
Show me how the IP and assets suddenly became worth 135 million less and yet at the same time the IP portfolio is GROWN and the distribution channels for our products is expanding!
I will be waiting for a educated, verified and legitimate argument against all of the above.
Mav
The same trading patttern...
Occured last week... we hit .012 and pulled back to .0089
This is how we stair step up in the midst of the wild wild west and all the dirty games they play to shake people out.
The day to day tick by tick means nothinf if your able to focus on the BIG picture.
Buy em load em lock and hold em!!
Mav
IT IS Obvious...
Some traders here are actively trying to stall the upward momentum... they are loosing grip.
Supposed shareholders who hold millions of shares who want the share price to go back to .0003...????
yeah that sure makes a lot of sense right??
lol
We get closer everyday to breaking out of these levels for good.
Rik its time to deliver the goods!!
Mav
okay... back to grade 9 math class...
LOL
This is potential of Nyloxin revenues from just the VA/Military:
6.5 million prescriptions in 2012. We know its more now! Doesn't even include the NSAID's....
Folks we get .5 million chronic prescription replacements - yearly supply:
500,000 * $38.25 monthly (45 extra strength*15% discount annual) * 12 (months) = 229,500,000 Revenues 1 year......
Sheesh... I would take 100,000 orders = 45,900,000 revenue (1.5% of 6.5 million prescriptions)....
100,000 orders is 1.5% of the total prescriptions in 2012. That number has definitely gone up. We are in the midst of a nation wide opiod crisis. You can guarantee that the market is going to want a opiod free painkiller.
EuroAmerican last year revenues have nothing to do with the above numbers. they are the broker. The get a commission from sales and their revenues to not reflect nor determine the potential revenue from marketing Nyloxin to the VA/Military.
THE FACT REMAINS. Right now as we speak EuroAmerican is actively marketing Nyloxin to the VA/Military. Absolutely NOBODY knows what the revenues are or will be. What I have presented here is a conservative 1.5% of the 2012 market share.
Hopefully I was talking slow enough for everyone to get it this time.... LOL
Mav
Buying OPPORTUNITY imo
Buy the cover.
If u ever heard that term this is one of those times. MMs manipulate the pps down take out stop losses and shake the tree. Cover their short down below and accumulate shares for the next push
People will look back at this moment and many will regret selling... and regret not buying imho. Mark it!
Mav
EuroAmerica actively marketing Nyoxlin...
To VA/Military is huge! I gave everyone clear numbers on what 1.5% of the market share would be...
HUGE revenue potential. It doesnt matter how big the broker company is. The point is mute.
LOL
Sounds like some lost some more shares by stacking the ask! Keep the buying pressure up. I am glad to add a few more shares down here
Mav
So EuroAmerica small company...
For now!
Facebook itself was created by a college student in his dormitory.
Twitter was created by 4 guys in an apartment.
Within a few short years they both became BILLION dollar empires because of creating ONE HOT PRODUCT at the right time... Timing is everything!!
If EuroAmerican is a small company they will work extra hard to get a product like Nyloxin out to the masses. It could be the product that takes them from 500k per year to 50 million a year!
ONE product is all it takes my friends. Every major success story comes from a revolutionary new idea brought to the right market at the right TIME.
The TIME IS NOW for opiod alternatives and Nyloxin is everything we have been looking for!
Military grade Nyloxin is strong enough to treat bullet wounds and opiod free!! You think the US military is going to interested!?! YES!
Mav
Nutra Pharma Files Provisional Patent for the Treatment of ALS
RECENT NEWS:
https://globenewswire.com/news-release/2018/04/10/1467763/0/en/Nutra-Pharma-Files-Provisional-Patent-for-the-Treatment-of-Amyotrophic-Lateral-Sclerosis-ALS.html
"Our primary drug for the treatment of Multiple Sclerosis is RPI-78M,” stated Rik J Deitsch, Chief Executive Officer of Nutra Pharma. “This drug had been used in previous trials for the treatment of ALS with varying results. We now believe that we have discovered the modifications that are necessary to allow RPI-78M to work effectively against ALS progression,” he continued. “We are filing new intellectual property surrounding these findings and will be working with experts in the field to create the new version of the drug. Once the drug is validated, we will move into animal models in ALS that will allow us to pursue broader trials and seek partners to further this research,” he concluded.
This is the market potential of ALS:
The global amyotrophic lateral sclerosis treatment market was valued at US$ 51.04 Million in 2016, and is expected to reach US$ 306.6 Million by 2025, expanding at a CAGR of 21.1% from 2017 to 2025.
ALS is a is a rare disorder that affects approximately 30,000 people in the United States, approximately 5,000 new cases are diagnosed each year in the United States. Currently, there is no cure for ALS however, treatments are available to control symptoms and to prevent complications. The U.S. Food and Drug Administration (FDA) has approved only two drugs for the treatment of ALS it includes Riluzole and Edaravone, other medications are prescribe to control ALS symptoms.
NPHC may have discovered a treatment to slow the progress of ALS! This is a huge development that paves the way to opening many doors. Again this is ONE of the many products we have in our IP portfolio.
I want to hear a valid substantiated argument that NPHC is only worth a 5 million dollar market cap... nothing but crickets... NPHC is possibly the most undervalued sub penny biotech in the OTC.
Mav
NPHC on the list with the BIG players...
Here is the article:
The global amyotrophic lateral sclerosis treatment market was valued at US$ 51.04 Million in 2016, and is expected to reach US$ 306.6 Million by 2025, expanding at a CAGR of 21.1% from 2017 to 2025.
ALS is a is a rare disorder that affects approximately 30,000 people in the United States, approximately 5,000 new cases are diagnosed each year in the United States. Currently, there is no cure for ALS however, treatments are available to control symptoms and to prevent complications. The U.S. Food and Drug Administration (FDA) has approved only two drugs for the treatment of ALS it includes Riluzole and Edaravone, other medications are prescribe to control ALS symptoms.
It is studied that in the base year 2016, Riluzole (Rilutek) was major revenue generating segment because riluzole was the only approved drug for a treatment of ALS, however patent expiry of Rilutek in 2013 has been negatively impacting the ALS treatment market growth. On the other hand, recently approved medication Edaravone (Radicava) expected to show highest growth rate during forecast period due to its applicability and higher cost would drive market growth. Moreover strong pipeline molecule such as AB-1010 (masitinib), Methycobal (mecobalamin), Arimoclomol, CK-2017357 (CK-357, tirasemtiv) would assist ALS treatment market growth during forecast period.
Key Market Movements:
Factors such as increasing treatment awareness, increase in incidence of ALS, strong pipeline molecules, rising geriatric population, favorable reimbursement policies in some countries and expected launch of newer medication would drive the growth of ALS treatment market globally.
Due to the higher number of unmet needs, manufacturers in the market are focusing on innovation and technological advances in treatment options would further influence the growth of ALS treatment market globally.
Company Profiles:
AB Science
Avicena Group
Biogen
BrainStorm Therapeutics
Covis Pharmaceutical Inc.
Cytokinetics Inc.
Eisai Co. Ltd.
GlaxoSmithKline plc.
Ionis Pharmaceuticals, Inc.
Mitsubishi Tanabe Pharma Corp.
Neuralstem Inc.
Neuraltus Pharmaceuticals Inc.
Newron Pharmaceuticals S.p.A.
Nutra Pharma Corp.
Pharnext SAS
Q-Therapeutics Inc.
link to the article: https://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=262292
NPHC is on the list with some MAJOR players here, take a look at some of their market caps!! NONE of them anywhere near 5 million MC.
NPHC will have its day and won't be held down here much longer.
Mav
2018 is the year for M&A in the pharmaceutical industry
Tax Overhaul Could Jolt Dollar as U.S. Companies Bring Home Cash
Big Pharma Corporations could repatriate as much as $400 billion in earnings and cash from abroad
https://www.wsj.com/articles/tax-overhaul-could-jolt-dollar-as-u-s-companies-bring-home-cash-1514206800
Mergers and acquisitions are anticipated to be huge with pharma and bio-techs...
Why 2018 is a make-or-break year for BIG Pharma:
Many drugmakers have neglected their pipelines, and will look to acquisitions to bolster them
https://www.marketwatch.com/story/why-2018-is-a-make-or-break-year-for-pharma-2017-12-19
FROM ARTCILE:
This year looks — at least on paper — like an unprecedentedly good setup for the pharmaceutical industry.
But behind the scientific breakthroughs, a Food and Drug Administration churning out approvals and drug-price regulation never materializing, the industry appears shockingly fragile.
Some of drugmakers’ most profitable products are aging, or simply old — nearly two decades old, in some cases — and staring down new competition.
Meanwhile, many big companies’ pipelines, typically a source of new development and the next billion-dollar drugs, are dry.
NPHC is poised to be a prime target for M&A in 2018. The IP portfolio and products would be a major addition to a big company looking for opiod alternatives and other disruptive products.
A Merger or acquisition is not out of the question here.
Mav
CELZ is a market cap correction play
They have way more going on than last year and are waaaay below the market cap from last year.
There procedure is ready to hit the market and they are poised to be a buy out target from bigger fish.
It is a very exciting time to get involved. It is apparent why the CEO is converting debt into common shares for himself . PPS appreciation is imminent imo
Mav
52wk high... CELZ is coming for you!
.55!!!
IMHO. Its possible! Thats only a 200 mil market cap!!
Buckle up!
Mav